

Commentary

A lack of a comparator group makes it hard to be sure whether computerised medical record system implementation achieved a better or worse outcome

Cite this article: de Lusignan S, Williams J, Hinton W, Munro N. A lack of a comparator group makes it hard to be sure whether computerised medical record system implementation achieved a better or worse outcome. *J Innov Health Inform.* 2016;23(1):485–487.

<http://dx.doi.org/10.14236/jhi.v23i1.867>

Copyright © 2016 The Author(s). Published by BCS, The Chartered Institute for IT under Creative Commons license <http://creativecommons.org/licenses/by/4.0/>

Author address for correspondence

Simon de Lusignan
Department of Health Care Management and Policy
University of Surrey
Guildford GU2 7XH, UK
Email: s.lusignan@surrey.ac.uk

Accepted April 2016

Simon de Lusignan

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.

John Williams

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.

William Hinton

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.

Neil Munro

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.

THE DIFFICULTY OF DRAWING CONCLUSIONS WITHOUT A CONTROL POPULATION

Burke et al.¹ draw conclusions about the impact of using a computerised medical record (CMR) system. However, we recommend exercising caution about the 5-year finding as there was no comparator group. There is therefore no means of establishing what would have happened to glycated haemoglobin (HbA1c) in patients in this group. We feel, however, that their 6-month conclusion is sound and that there may be important lessons about the possible detrimental impact of implementing a CMR system.

DECLINE IN PANCREAS β -CELL FUNCTION MAY ACCOUNT FOR WHY DIABETES CONTROL DETERIORATES OVER TIME

There are other elements that may have contributed to glycaemic control in these patients. β -cells are cells in the pancreas that produce the insulin required to control blood glucose. We know that β -cells function declines over time. In addition, the tissues of body become resistant to one of the primary actions of insulin – to facilitate the transport of glucose into cells from the bloodstream. The combination of declining β -cell function and insulin resistance leads to an inexorable decline in glycaemic control and a rise in blood glucose over time.

The decline in β -cell function in Type 2 diabetes starts a decade or more before diagnosis and continues throughout the course of the disease itself. Homeostasis model assessment has been used to quantify the decline in β -cell function. The U.K. Prospective Diabetes Study (UKPDS) demonstrated that β -cell function continued to deteriorate in association with progressively increasing hyperglycaemia despite treatment with glucose lowering agents.²

Attempts to quantify β -cell failure include the work of Wallace and Matthews,³ who demonstrated HbA1c changes with time (Figure 1, reproduction from Wallace




Figure 1 Decline in HbA1c (A1C on y-axis) over years with diabetes³

and Matthews). In UKPDS, the mean, the rate of change reported with one of the commonest used glucose lowering medication (glibenclamide), was 0.5% HbA1c/year (they more precisely termed this coefficient of decline in β -cell function).³

Over 5 years, the overall change in mean HbA1c reported by the authors of the current study was around 0.12%. This would appear to be much lower than the rate of decline observed in Wallace and Matthew's work³.

COMPARING THE OVERALL CHANGE IN HbA1c WITH THE RATE OF CHANGE IN THE ROYAL COLLEGE OF GENERAL PRACTITIONERS RESEARCH AND SURVEILLANCE CENTRE DATABASE

To test whether this was a reasonable change in HbA1c, we explored the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database (www.rcpg.org.uk).⁴ We identified 28,126 people with Type 2 diabetes. Over a 5-year period, we found that the mean change in HbA1c (2010 to 2015) was from 7.3% to 7.5% and the median change was 7.0% to 7.2% (Table 1 and Figure 2). A Wilcoxon signed rank test with continuity correction shows

the difference to be highly significant ($p < 0.001$). Given the confidence intervals in both sets of data, we see no evidence in difference in rate of change between this USA-based military-based population and the U.K. primary care population. However, further research would be required to be certain that there were no differences.

SUMMARY – THE PROCESS OF ADOPTION OF A COMPUTERISED RECORD SYSTEM MAY BE ASSOCIATED WITH A TEMPORARY DECLINE IN QUALITY OF CARE

The process of implementation of CMR may well have been associated with a dip in the quality of care of people with diabetes. This difference is reported in this paper at all levels of glycaemic control. Among the primary care informatics community, there is a lack of consensus about how to get CMR system implementation right, in a way that there is not about other core areas of informatics theory.⁵

Our conclusion is that the importance of this paper is primarily in flagging the 'blip', the deterioration in control that appears to occur after the implementation of a CMR system. New implementation strategies could be tested against this benchmark.

Table 1 Change in glycated haemoglobin (HbA1c) over the previous 5 years in the RCGP RSC database. International Federation of Clinical Chemists units are used routinely in UK, the units being in mmol/mol. Diabetes Control and Complications Trial is well established and uses percentage as units. Higher levels of both are associated with more complications in diabetes

	Five years ago		Latest HbA1c	
	IFCC	DCCT	IFCC	DCCT
Mean (95% CI)	56.3 (56.12-56.48)	7.3%	58.3 (58.01-58.49)	7.5%
SD	15.2	3.5%	16.2	3.6%
Median	53	7.0%	55	7.2%
IQR	15.3	3.5%	18.0	3.8%




Figure 2 Box plot showing the change in glycated haemoglobin (HbA1c) over 5 years in the RCGP RSC database. The 'box' of the box plot shows the median with the 25th and 75th centiles. The whiskers on either side of the box show the 3rd and 97th centiles with outliers shown as individual dots ($N = 28,126$). N.B. HbA1c is in different units – Table 1 provides comparative data

REFERENCES

1. Burke HB, Becher DA, Hoang A and Gimbel RW, The adoption of an electronic health record did not improve A1c values in Type 2 diabetes. *J Innov Health Inform*. 2016;23(1):433–438.
2. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. *Diabetes* 1995; 44:1249–1258.
3. Wallace TM and Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. *Diabetic Medicine* 2002; 19:465–469.
4. Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. *BMJ Open*. 2016 Apr 20;6(4):e011092. doi:10.1136/bmjopen-2016-011092.
5. Liyanage H, Correa A, Liaw ST, Kuziemy C, Terry AL and de Lusignan S. Does Informatics enable or inhibit the delivery of patient-centred, coordinated, and quality-assured care: a Delphi Study. A Contribution of the IMIA Primary Health Care Informatics Working Group. *Yearbook of Medical Informatics* 2015;10(1):22–9. doi: 10.15265/IY-2015-017.